tRNA Modification Promotes Cancer and Chemoresistance | Arraystar



Publications \| Promo

Molecular Cancer | A-to-I tRNA Modification Promotes Cancer and Chemoresistance

Fig. 1. Increased A-to-I tRNA modification by overexpression of ADAT2 editing enzyme (ADAT2-OE) promotes cancer xenograft growth[1].

Customer Success Story

A-to-I is the top tRNA modification in colorectal cancer. ADAT2-driven tRNA modification has been discovered to promote colorectal cancer tumorigenesis and chemoresistance via HDAC7-WNT/β-catenin axis[1]. In the study, Arraystar tRNA pretreatment kit was used in tRNA profiling. The findings further suggest ADAT2 and the tRNA modification as a therapeutic target and an independent prognostic marker.

References

[1] Cheng CH. et al (2026) "ADAT2-mediated A-to-I tRNA modification promotes oncogenic translation and colorectal cancer progression and chemoresistance." Mol Cancer [PMID:41845367]

Arraystar rtStar™ tRNA Pretreatment & First-Strand cDNA Synthesis Kit

• Efficient removal of internal modifications in tRNAs to ensure the proceeding of reverse transcriptase during cDNA synthesis, whereas regular cDNA synthesis method cannot.

• Magnitudes of increase in tRNA detection sensitivity and quantification accuracy with the treated compared with untreated samples.

Catalog No. AS-FS-004

Order Now!

Turnkey Solutions for tRNA Research

From tRNA Expression, Modification, Charging to Disease Mechanisms

Arraystar provides comprehensive sequencing, microarray, PCR, and LC–MS services to support tRNA charging, expression, and modification studies, empowering advanced research into tRNA function and disease mechanisms.

Single-Base tRNA Modification Seq NEW!

m7G (TRAC-Seq)

m7G (m7G-Quant-Seq)

Ψ (BID-Seq)

Ψ (BACS-Seq)

m5C (BS-Seq)

m1A (m1A-Quant-Seq)

m3C (HAC-Seq)

m3C (m3C-IP-Seq)

2′-O-Me (NM-Seq)

D (CRACI-Seq)

ac4C (RedaC:T-Seq)